ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc (CPRX)

16.56
-0.36
( -2.13% )
Updated: 11:56:03

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
16.56
Bid
16.55
Ask
16.57
Volume
167,879
16.51 Day's Range 16.95
11.09 52 Week Range 17.495
Market Cap
Previous Close
16.92
Open
16.91
Last Trade
100
@
16.56
Last Trade Time
11:57:13
Financial Volume
$ 2,808,286
VWAP
16.728
Average Volume (3m)
1,357,970
Shares Outstanding
117,863,258
Dividend Yield
-
PE Ratio
27.36
Earnings Per Share (EPS)
0.61
Revenue
398.2M
Net Profit
71.41M

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of p... Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Catalyst Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CPRX. The last closing price for Catalyst Pharmaceuticals was $16.92. Over the last year, Catalyst Pharmaceuticals shares have traded in a share price range of $ 11.09 to $ 17.495.

Catalyst Pharmaceuticals currently has 117,863,258 shares outstanding. The market capitalization of Catalyst Pharmaceuticals is $1.95 billion. Catalyst Pharmaceuticals has a price to earnings ratio (PE ratio) of 27.36.

CPRX Latest News

Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of...

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on...

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on...

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing...

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.251.5328019619916.3117.0316.11108383816.56909199CS
41.368.9473684210515.217.0314.47109465415.55995569CS
122.3616.619718309914.217.49514.16135797015.76699296CS
262.9321.496698459313.6317.49513137254615.14286835CS
524.3936.072308956512.1717.49511.09139809813.99967042CS
15610.88191.5492957755.6822.114.81161271812.61420275CS
26012.74333.5078534033.8222.112.5517175948.92970847CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGOLMGO Global Inc
$ 1.0601
(361.11%)
224.34M
MGRXMangoceuticals Inc
$ 0.7099
(180.59%)
192.82M
FLJFLJ Group Limited
$ 1.43
(84.04%)
22.39M
BRLSBorealis Foods Inc
$ 7.35
(83.75%)
719.22k
BDRXBiodexa Pharmaceuticals PLC
$ 2.315
(82.28%)
102.19M
CTNTCheetah Net Supply Chain Service Inc
$ 3.15
(-78.66%)
14.45M
GWAVGreenwave Technology Solutions Inc
$ 0.06095
(-61.42%)
421.54M
LUXHLuxUrban Hotels Inc
$ 0.2532
(-43.73%)
8.71M
IPWiPower Inc
$ 1.30
(-36.59%)
953.88k
AONCAmerican Oncology Network Inc
$ 1.80
(-31.56%)
187.77k
GWAVGreenwave Technology Solutions Inc
$ 0.06095
(-61.42%)
421.54M
CRKNCrown Electrokinetics Corporation
$ 0.1468
(-26.23%)
237.55M
MGOLMGO Global Inc
$ 1.0601
(361.11%)
224.34M
MGRXMangoceuticals Inc
$ 0.7099
(180.59%)
192.82M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1442
(11.14%)
162.1M

CPRX Discussion

View Posts
north40000 north40000 1 week ago
New CPRX CEO Richard Daly is interviewed by IBD at investors.com. Pipeline discussion includes 3 rare disease, orphan drugs—Firdapse for treatment of neuromuscular conditions in small cell lung cancer patients, Fycompa for epilepsy and newly licensed Agamree with an NDA filed by partner Santhera for Duchenne muscular dystrophy.

Daly has previous experience with ABT, BMY, AZN, Takeda and 9 years on BOD of CPRX.

We hold 17k shares of CPRX in 2 portfolios.
👍️0
georgie18 georgie18 2 months ago
Actually went to $22 retraced to $11 range...Now $17 range...🥳
👍️0
Monksdream Monksdream 2 months ago
CPRX over $10
👍️0
tw0122 tw0122 7 months ago
FDA approval Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Source: GlobeNewswire Inc.

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals ("Santhera") has obtained U.S. Food and Drug Administration ("FDA") approval for AGAMREE® (vamorolone) oral suspension 40 mg/mL for use in treating Duchenne Muscular Dystrophy ("DMD") in patients aged two years and older. AGAMREE offers a novel corticosteroid treatment option for DMD, addressing a significant unmet medical need. In July 2023, Catalyst secured the exclusive North American license and commercial rights for AGAMREE from Santhera for DMD and other potential indications, bolstering its neuroscience commercial portfolio with a highly synergistic neuromuscular asset. As part of that transaction, Santhera will promptly transfer the approved New Drug Application for AGAMREE to Catalyst.
FDA’s approval of AGAMREE® was based on the data from the pivotal Phase 2b VISION-DMD study as supplemented with safety information collected from three open-label studies, including extension studies. In these trials, AGAMREE was administered at doses ranging from 2 to 6 mg/kg/day, extending for a period of up to 48 months. Compared with current standard-of-care corticosteroids, this novel corticosteroid treatment exhibited comparable efficacy, with data suggesting a reduction in adverse events, notably related to bone health, growth trajectory, and behavior.

“We strongly believe that this novel steroid has the transformational potential to make a significant difference for patients living with Duchenne Muscular Dystrophy and potentially other chronic inflammatory diseases. The approval of AGAMREE underscores the potential of reshaping the DMD treatment paradigm for this life-threatening rare disease. The addition of AGAMREE expands our rare neuromuscular disease portfolio, and we look forward to executing on our proven commercial capabilities to bolster our long-term growth potential,” said Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals. “Our unwavering commitment extends beyond this important milestone as we are resolute in our mission to ensure that DMD patients in the U.S. have access to this treatment option as we believe that AGAMREE may offer the potential of increasing the duration of ambulation and mobility in these patients, thereby significantly improving their overall quality of life. We expect to launch the product in the first quarter of 2024. At that time, we will introduce a comprehensive financial assistance program aimed at helping ensure accessibility and minimizing patient co-pays and deductibles, thereby enhancing affordability for all DMD patients. We look forward to successfully commercializing this product with a continued commitment to serving our patient communities."

Upon the transfer of AGAMREE's NDA into its neuromuscular franchise, Catalyst will harness its product portfolio synergies by leveraging its well-established expertise and proven commercial capabilities. The Company plans to launch the product in Q1 2024, spearheaded by its seasoned and experienced U.S. commercial and medical affairs neuromuscular teams.

AGAMREE was granted Orphan Drug and Rare Pediatric Disease designations status for DMD in the U.S. and will be eligible for seven years of orphan drug exclusivity upon approval date and has issued pending patents that could provide protection until 2040.

👍️ 1
georgie18 georgie18 3 years ago
CPRX...$6.95s clearing here on the Upper Bollie Breakout...:party:
[11:33 AM]
georgie18 — 11/02/2021
CPRX...$6.17...Psar flipped Bullish...MACD ready to Cross Positive...Money Flow/Aroon both suggest a strong Upside move...Break/hold $7.67 sets all time highs and Blue Skies territory with NO Upside Resistance...imo...we shall see... https://schrts.co/xkZTZjMN ...:party:
👍️0
georgie18 georgie18 3 years ago
CPRX...$6.45...Pushing the Upper Band here...:party:
[9:03 AM]
georgie18 — 09/24/2021
CPRX...$5.05..Loading this on the add here...Psar flipped Bullish...watch for a Double Top Break/Hold in the $6.30 range...:party:
👍️0
georgie18 georgie18 3 years ago
CPRX...$6.17...Psar flipped Bullish...MACD ready to Cross Positive...Money Flow/Aroon both suggest a strong Upside move...Break/hold $7.67 seta all time highs and Blue Skies territory with NO Upside Resistance...imo...we shall see... :party:https://schrts.co/xkZTZjMN ...

[7:51 AM]
georgie18 — 10/28/2021
CPRX...$5.87...Back in here on the Bullish Pole N Flag Reversal Pattern to the Upside off the 100ma support...imo...we shall see...:party:
👍️0
georgie18 georgie18 3 years ago
CPRX...$6.10...Psar flipped Bullish ...:party:
[10:23 AM]
georgie18 — 10/28/2021
CPRX...$5.87...Back in here on the Bullish Pole N Flag Reversal Pattern to the Upside off the 100ma support...imo...we shall see...:party:
👍️0
LearningEveryTrade LearningEveryTrade 3 years ago
With Lawsuit WIN, let's get Bought by BP

I like 11.00 for that.
👍️0
georgie18 georgie18 3 years ago
CPRX...$6.42...Breaking the Double top here...If she holds then $7 plus is coming...imo...we shall see...:party:
[11:35 AM]
georgie18 — 09/24/2021
CPRX...$5.05..Loading this on the add here...Psar flipped Bullish...watch for a Double Top Break/Hold in the $6.30 range...:party:
👍️0
georgie18 georgie18 3 years ago
CPRX...$5.77s clearing here...on the Upper Bollie Break...off the $5.05 range alert...:party:

georgie18 — Today at 10:05 AM
georgie18 — 09/24/2021
CPRX...$5.05..Loading this on the add here...Psar flipped Bullish...watch for a Double Top Break/Hold in the $6.30 range...:party:
👍️0
north40000 north40000 3 years ago
https://media.ca11.uscourts.gov/opinions/pub/files/202013922.pdf
👍️0
north40000 north40000 3 years ago
CPRX wins its Orphan Drug case in the 11th Circuit Court of Appeals.
👍️0
georgie18 georgie18 3 years ago
CPRX...$5.05..Loading this on the add here...Psar flipped Bullish...watch for a Double Top Break/Hold in the $6.30 range...
[7:59 AM]
georgie18 — 09/09/2021
CPRX...$5.18...Back in here on the Bullish Piercing Line Reversal Candle...Break/Hold $7.67 and its a Blue Skies Chart with NO Topside Resistance...imo...we shall see...
👍️0
georgie18 georgie18 3 years ago
CPRX...$6.05...Beauty move on the CnH Breakout....Looking for a Blue Skies Breakout on the Double Top Break/Hold in the $7.60 range...No Topside Resistance if we get that Double Top Breakout...

Took some profit in the $5.50 range...back in
looking for the $10 range...imo...we shall see...

georgie18 — 03/01/2021
CPRX...$3.89...Cup N Handle Continuation Pattern setting up here...Handle needs to Break/Hold the $5 range for confirmation...imo...we shall see...

Chart...https://schrts.co/BkZsqTNi
👍️0
georgie18 georgie18 3 years ago
CPRX...$5.09s clearing here...
👍️0
georgie18 georgie18 3 years ago
CPRX...$4.94...Psar flipped to a Bullish buy Position...:partying_face:
👍️0
georgie18 georgie18 3 years ago
CPRX...$4.37...CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that its Board of Directors has authorized the repurchase of up to $40 million of shares of Catalyst's outstanding common stock.

georgie18 Monday, 03/01/21 05:56:40 AM
Re: None 0
Post #
4106
of 4108
CPRX...$3.89...Cup N Handle Continuation Pattern setting up here...Handle needs to Break/Hold the $5 range for confirmation...imo...we shall see...

Chart...https://schrts.co/BkZsqTNi
👍️0
NCBchBoy NCBchBoy 3 years ago
Nice article.

https://www.investopedia.com/investing/biotech-stocks/?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral
👍️0
georgie18 georgie18 3 years ago
CPRX...$3.89...Cup N Handle Continuation Pattern setting up here...Handle needs to Break/Hold the $5 range for confirmation...imo...we shall see...

Chart...https://schrts.co/BkZsqTNi
👍️0
JimsZ JimsZ 3 years ago
I guess this board isn't active anymore...... To the MOON anyways
👍️0
JimsZ JimsZ 3 years ago
Volume before price, although quite a rise with this minimally higher volume.


36 mil float and 10% of outstanding short! Go CPRX
👍️0
georgie18 georgie18 3 years ago
CPRX...$3.64...Psar flipped to a Bullish buy Position...:party:
👍️0
georgie18 georgie18 3 years ago
CPRX...$3.69...in the P/M...
👍️0
LiquidPorsche LiquidPorsche 3 years ago
Feeling the Bern? CPRX ?
👍️0
georgie18 georgie18 3 years ago
CPRX...$3.80...on the P/M gappa...
[7:07 AM]
georgie1811/04/2020
CPRX...$3.32...Psar flipped to a Bullish By Position...on volume...
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.52...
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.42...in the P/M...8K...https://www.otcmarkets.com/filing/html?id=14491440&guid=EvceUWsDF2zCrth

Q3-20 Financial Results

Product revenue, net in the third quarter of 2020 was $29.2 million, compared to $30.9 million for the third quarter of 2019.

Operating income for the third quarter of 2020 was $11.7 million, compared to $13.8 million in the third quarter of 2019.

Reported net income of $43.3 million, or $0.42 per basic and $0.41 per diluted share, in the third quarter of 2020, compared with net income of $13.6 million, or $0.13 per basic and diluted share, for the third quarter of 2019.

Net income in the third quarter of 2020 includes $31.3 million ($0.30 per basic and $0.29 per diluted share) of benefit from recording of deferred tax asset, upon reversal of valuation allowance.

👍️0
whytestocks whytestocks 4 years ago
News; $CPRX Small Cap Stocks Are Surging; 3 Penny Stocks To Buy Under $4

3 Penny Stocks To Buy For Under $4 Are you looking for small cap stocks right now? While many of these could be penny stocks , not all things defined as “small-cap” trade below $5 a share. In fact, the main focus when looking at any “cap stock” is the...

In case you are interested CPRX - Small Cap Stocks Are Surging; 3 Penny Stocks To Buy Under $4
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.32...Psar flipped to a Bullish By Position...on volume...
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.23...CORAL GABLES, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to Catalyst Pharmaceuticals for Firdapse® (amifampridine), U.S. Patent No. 10,793,893, Methods of Administering 3,4-Diaminopyridine, expiring April 7, 2034.
👍️0
LiquidPorsche LiquidPorsche 4 years ago
Judges decision really hurt this stock but what are adult patients choosing for their Rx. A generic compounded untested pill that needs to be refrigerated or the branded, better version, well studied Rx with the patient assistance program as well as coverage. Orphan Branded meds are important!! Follow the law on the books !!!
👍️0
north40000 north40000 4 years ago
Florida District Court followed magistrate’s recommendation, granted summary judgment to FDA. CPRX will appeal that judgment to 11th Cir.
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.30s clearing here...
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.42...in the P/M...Psar flipped to a Bullish buy Position...
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.30...Bullish One White Soldier Reversal Pattern to the Upside...CPRX coming out of the Oversold Position as the Pincher Squeeze starts to diverge...

Psar flipped to a Bullish Buy Position...Macd Crossed positive...Been Accumulating in the $3/$5 range...Looking for a Blue Sky Breakout in the $7.50 range on the Break/Hold of a Long Term Double Top...imo...we shall see...

Chart...http://schrts.co/TsEyaYEd

Long Term Double Top Chart....http://schrts.co/cqbaYjwh
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.78...in the P/M...Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada...

https://www.otcmarkets.com/stock/CPRX/news/story?e&id=1672950
👍️0
whytestocks whytestocks 4 years ago
News: $CPRX 3 Stocks Robinhood Investors Love

Robinhood, a free app offering commission-free trading of stocks, options, and more, has attracted a lot of attention in recent months. Many investors who use it seem drawn to specific names, and they're not necessarily stocks that receive a lot of coverage. Among Robinhood's 100 most popular s...

Got this from CPRX - 3 Stocks Robinhood Investors Love
👍️0
ClayTrader ClayTrader 4 years ago
* * $CPRX Video Chart 08-12-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
georgie18 georgie18 4 years ago
CPRX...$3.87...in the P/M...CORAL GABLES, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/128,672. The allowed application, "Methods of Administering 3,4-Diaminopyridine", claims a method of treating a human patient diagnosed with a 3,4-DAP sensitive disease by administering 3,4-DAP (or salts thereof) to slow acetylating patients having certain mutations in each allele of the NAT2 gene.

https://www.otcmarkets.com/stock/CPRX/news/story?e&id=1667289
👍️0
georgie18 georgie18 4 years ago
CPRX...$4.24...added here on the Reversal Candle off the Oversold Pincher Squeeze...

👍️0
georgie18 georgie18 4 years ago
CPRX...$4.14...in the P/M...Bullish Harami Cross formed on the close as the Oversold Pincher starts to Squeeze here...adding in this range...

My $3.90 range shares looking better my $4.90 range shares not so good at the moment...averaging down on the pattern...

Chart...http://schrts.co/NZBaGirw
👍️0
georgie18 georgie18 4 years ago
CPRX...$4.14...in the P/M...CORAL GABLES, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Canada’s national healthcare regulatory agency, Health Canada, has approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with Lambert-Eaton myasthenic syndrome (LEMS), an ultra-rare, debilitating and potentially life-threatening neurodegenerative condition.
👍️0
north40000 north40000 4 years ago
Does anyone have a link to the full text of the Florida magistrate’s recommendation to the District Court Judge? Tia.
👍️0
georgie18 georgie18 4 years ago
CPRX...$4.32...in the A/H...
[4:10 PM]
georgie18Today at 10:01 AM
CPRX...$3.93...added here on the dip...not reading this one well at all...lets see what happens...
👍️0
LiquidPorsche LiquidPorsche 4 years ago
Orphan Drug Designations are in jeopardy with these “cancel culture” magistrate judges making poor decisions not based in practicing law standards. That’s my own opinion. If they want to change the laws and so forth that’s fine. But then I would change my behavior on investing my hard earned $s.
👍️0
georgie18 georgie18 4 years ago
CPRX...$3.93...added here on the dip...not reading this one well at all...lets see what happens...
👍️0
georgie18 georgie18 4 years ago
CPRX...$4.91...Bullish Harami Reversal Pattern to the Upside formed on the close...

Looking to Break/Hold the $5.20 range Resistance and head towards the Double Top break in the $7.50 range...No resistance after that just Blue Skies...imo...we shall see...

Previous alert at $4.55 failed to push past that $5.20 range resistance...

Chart...http://schrts.co/fdpFeseE

Interesting ...My P/M buys that went through 20 minutes ago on CPRX have not showed up on L2...
👍️0
DrChess DrChess 4 years ago
Thank you, likewise
👍️0
Limey42 Limey42 4 years ago
A win and the price jumps.....this company is in great shape either way GLTU!
👍️0

Your Recent History

Delayed Upgrade Clock